FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Scientists have created a new type of super-strong antibody that could significantly enhance cancer immunotherapy. In an ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first ...

New research from the University of Cincinnati demonstrates how specially engineered bacteria taken orally can operate as a ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

Another significant effect observed following treatment with anti-P3 antibodies was the improvement in the interaction dynamics between mitochondria and cytoplasmic lipid droplets, indicating a ...

Clinicians have limited options for treatment of individuals sick with ... polyclonal collection of antibodies collected and pooled from many donors and is poorly suited for widespread use.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, ...